title: Insurmountable beta receptor blockade by ICI 147,798 in rabbits.
abstract: In rabbits, the characteristics of cardiac beta-1 receptor blockade produced by ICI 147,798, a novel beta receptor blocking agent with diuretic properties, were evaluated and compared with those of propranolol. In conscious rabbits, i.v. injections of 0.31, 1.0 and 3.1 mg/kg of ICI 147,798 and 1.0 mg/kg of propranolol caused significant bradycardia. ICI 147,798 produced a dose-dependent shift to the right of the dose-response (chronotropic) curve of isoproterenol with suppression of the maximal tachycardia, an effect characteristic of insurmountable beta receptor blockade. Propranolol also produced a shift to the right of the dose-response curve of isoproterenol without affecting the maximal tachycardia. ICI 147,798-induced antagonism was specific for beta adrenoceptors as it failed to modify the effects of acetylcholine, angiotensin II, phenylephrine, adenosine, histamine and prostaglandin E2 on mean arterial pressure and heart rate. In rabbits with prior autonomic blockade, ICI 147,798, like propranolol, failed to inhibit the positive chronotropic effects of theophylline which are mediated by postreceptor mechanisms. In reserpinized rabbits, ICI 147,798 was found to have no intrinsic sympathomimetic activity. Unlike the effects of propranolol, which were attenuated by first-pass through the hepatic vascular bed, the effects of ICI 147,798 were unaffected suggesting an absence of first-pass metabolism. The effects of propranolol (1.0 mg/kg i.v.) were not detectable at 24 hr after injection, whereas significant beta receptor blocking activity was still present at 24 hr after ICI 147,798 (1.0 mg/kg i.v.). The results suggest that ICI 147,798 is a specific, long-acting, insurmountable beta-1 receptor blocking agent without intrinsic sympathomimetic activity.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Department of Medicine, University of Wisconsin Medical School, Sinai Samaritan Medical Center, Milwaukee.
authors.forename: V S
authors.initials: VS
authors.lastname: Murthy
authors.forename: T F
authors.initials: TF
authors.lastname: Hwang
authors.forename: R
authors.initials: R
authors.lastname: Wurm
authors.forename: M E
authors.initials: ME
authors.lastname: Zagar
authors.forename: R A
authors.initials: RA
authors.lastname: Keith
authors.forename: S T
authors.initials: ST
authors.lastname: Kau
authors.forename: A I
authors.initials: AI
authors.lastname: Salama
authors.forename: R E
authors.initials: RE
authors.lastname: Giles
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000494:pharmacology*; D000818:Animals; D001794:Blood Pressure / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D008297:Male; D011433:Propranolol / Q000494:pharmacology; D011719:Pyrazines / Q000493:pharmacokinetics / Q000494:pharmacology*; D011817:Rabbits; D011943:Receptors, Adrenergic, beta / Q000187:drug effects*; D013806:Theophylline / Q000494:pharmacology
chemical_list: D000319:Adrenergic beta-Antagonists; D011719:Pyrazines; D011943:Receptors, Adrenergic, beta; C053707:ICI 147798; D011433:Propranolol; D013806:Theophylline